NMS·Healthcare·$212M·#143 / 520 in Healthcare
CDXS Codexis, Inc.
59SPECULATIVE
CATEGORY BREAKDOWN
GROWTH30
QUALITY60
STABILITY63
VALUATION91
GOVERNANCE67
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
+18.6%
30
> 50% strong
Gross Margin
Revenue retained after direct costs
86.7%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
31 months
94
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
144.9%
1
< 25% strong
Price / Sales
Market cap relative to trailing revenue
2.7x
91
< 3x strong
Rule of 40
Growth rate plus operating margin
-36
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
7.4%
52
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+0.7%
96
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE CDXS WITH…
OR QUICK-COMPARE SECTOR PEERS
RELATED RESEARCH
4 Best Small-Cap Synthetic Biology Stocks — May 2026May 2, 2026SCORE ALERT
Get notified when CDXS's score changes by 5+ points.
DATA INFO
Last updated: Jul 1, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.